Physician profile
Mary E Cavnar-Johnson
NPI 1467569400
$6,372.19
in general payments reported to CMS, 2019-2025
40 companies · $772 in 2025
The $772 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $620 · 2021: $2,314 · 2022: $651 · 2023: $849 · 2024: $778 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,398.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,299.66 | 2021 | |
| Novo Nordisk INC | $754.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $711.49 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $430.91 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $406.47 | 2021-2025 | Qulipta, Ubrelvy |
| Pfizer INC. | $338.86 | 2019-2025 | |
| Amgen INC. | $330.75 | 2019-2025 | Otezla, Repatha, Repatha |
| Sumitomo Pharma America, INC. | $209.08 | 2023-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $194.61 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $184.86 | 2020-2024 | Veozah |
| Abbott Laboratories | $179.07 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Paratek Pharmaceuticals, INC. | $112.60 | 2024-2025 | Nuzyra, Xhance |
| Astrazeneca Pharmaceuticals LP | $110.89 | 2019-2025 | Airsupra |
| Currax Pharmaceuticals LLC | $89.94 | 2020-2022 | |
| Inspire Medical Systems, INC. | $89.18 | 2023 | Inspire |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $87.19 | 2022-2023 | Unithroid |
| Biohaven Pharmaceutical Holding Company LTD. | $71.67 | 2022 | |
| Eisai INC. | $69.78 | 2020-2021 | |
| Allergan, INC. | $66.44 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.14 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $62.95 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $50.92 | 2023-2025 | Seglentis, Livalo, Zoryve |
| Exact Sciences Corporation | $48.20 | 2023-2025 | Cologuard Collection Kit |
| Edwards Lifesciences Corporation | $44.11 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Acella Pharmaceuticals, LLC | $41.96 | 2024-2025 | NP Thyroid 60 |
| Dexcom, INC. | $37.74 | 2024-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $37.25 | 2023-2024 | Trintellix |
| Genentech USA, INC. | $31.98 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $31.05 | 2020 | |
| Ibsa Pharma INC. | $25.54 | 2020 | |
| Radius Health, INC. | $19.23 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.11 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $18.30 | 2021 | |
| Amarin Pharma, INC. | $17.63 | 2020 | |
| Inari Medical, INC. | $16.80 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Horizon Therapeutics Plc | $15.23 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.74 | 2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $13.85 | 2022 | |
| Bausch Health US, LLC | $12.19 | 2019 | |
| Idorsia Pharmaceuticals US INC | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Cavnar-Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.